WCM Lymphoma

Take a BITE out of cancer! Dr @mmejia91 recently came on the @WeillCornell #CancerCast podcast to discuss how bispecific t-cell engager, or BiTE, therapy works to target #cancer, common side effects & how this treatment differs from other #immunotherapy bit.ly/4lH4Kc8

Watch Dr. John Allan discuss strategies for treating relapsed or refractory chronic lymphocytic leukemia (CLL), including sequencing considerations: bit.ly/46Ra1If (cc: @medscape)

Dr. Jia Ruan presented at the @lymphoma Mantle Cell Lymphoma Scientific Consortium and Workshop on a phase 2 #ClinicalTrial of a combination therapy for patients with treatment-naive mantle cell #lymphoma. Learn more: bit.ly/4rRz8T2 (cc: @CancerNetwrk)

Dr. John Allan provided expert commentary on #research presented at #ASH25 evaluating a BTK inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic #lymphoma (SLL): bit.ly/4tvQ8A9

Dr. John Allan is speaking at Lymphoma Talk: New York, an in-person program on 3/5 hosted by @lymphoma where #lymphoma experts share information with patients about all forms of the disease. Register here: bit.ly/4bTU738

Join Dr. Erin Mulvey this afternoon for the Ask the Doctor About #Lymphoma series hosted by @lymphoma where she’ll be discussing how to navigate relapsed/refractory disease and answering live questions. Learn more and register: bit.ly/3ZvhCrV

Dr. Erin Mulvey chimed in on an article about five things to expect from chronic lymphocytic leukemia (#CLL) treatment in 2026, including the use of #PrecisionMedicine, targeted therapy, and more : bit.ly/4szaPum

Part 3 of the @Blood_Cancers #CLL roundtable featured continued discussion on targeted approaches to CLL treatment. Hear more from our own Dr. Erin Mulvey: bit.ly/3YGTkuw

In part 2 of the @Blood_Cancers #CLL roundtable discussion, Dr. Erin Mulvey spoke alongside other #lymphoma experts about targeted treatment strategies for CLL: bit.ly/4pHgXy6

In another @VJHemOnc video, Dr. @etenhacken discussed the genetic and metabolic drivers of Richter's transformation: bit.ly/49WVkVK

Dr. Erin Mulvey joined a @Blood_Cancers roundtable discussion featuring #Lymphoma experts from across the US to discuss the use of BTK inhibitors for chronic lymphocytic #leukemia (#CLL): bit.ly/4jFGkix

WATCH: Dr. @etenhacken spoke with @VJHemOnc about the progression from chronic lymphocytic leukemia (#CLL) to Richter’s transformation: bit.ly/4qVAFqS

Dr. Erin Mulvey joined a panel of #lymphoma experts to discuss BTK inhibitors for the treatment of chronic lymphocytic leukemia (CLL): bit.ly/49hVBCq (cc: @Blood_Cancers)

Dr. Sarah Rutherford presented at #ASH25 on improving outcomes in diffuse large B-cell #Lymphoma (DLBCL). Learn more: bit.ly/4ajfGtc

Learn more about how liquid biopsy can unlock clues about #cancer by analyzing circulating tumor DNA (ctDNA), cell free DNA, and circulating tumor cells (CTCs) via the @WeillCornell #CancerCast podcast: bit.ly/49szlGy

Listen to Dr. Sarah Rutherford on the @OncLive On Air #podcast where she discusses the use of circulating tumor DNA (ctDNA) to help shape #Lymphoma treatment strategies: bit.ly/48q1Dk4

Dr. Sarah Rutherford spoke with @OncLive about using minimal residual disease (MRD) testing and circulating tumor DNA (ctDNA) monitoring as tools for managing #Lymphoma: bit.ly/4oIzOYW

#Lymphoma expert Dr. Richard Furman and Dr. Gail Roboz of @WCMLeukemia joined the @WeillCornell #CancerCast podcast to talk about the #ASH25 #research they were most excited about. Listen here: bit.ly/3KlVYlV

Dr. Vicky Revuelta shared results at #ASH25 from #research looking at differences in gene activity in diffuse large B-cell #Lymphoma (DLBCL) patients with African ancestry bit.ly/44Terx0 (cc: @LCerchietti)

#Research presented at #ASH25 by first-year @WeillCornell Hematology & Medical Oncology fellow Dr. @EastonNeela33 looked at prophylactic treatment for neurotoxicity after chimeric antigen receptor T cell (CAR-T) therapy in a subset of #Lymphoma patients: bit.ly/3XufWOn